Durham John, Low Melissa, McLeod Deborah
Ora Toa Medical Centre, Porirua, New Zealand.
N Z Med J. 2003 Jun 20;116(1176):U476.
To determine the views of general practitioners (GPs) in relation to screening for prostate cancer.
A questionnaire was sent to a random, national sample of 575 New Zealand general practitioners, stratified to include equal numbers of rural and urban GPs.
The response rate to the questionnaire was 66.3%. A 55-year-old man presenting for an annual checkup or requesting advice about screening for prostate cancer would be given a prostate specific antigen (PSA) test by 74% of GPs. If the same man had a family history of prostate or breast cancer, 93% of GPs would carry out a PSA test. Most GPs overestimated the effectiveness of screening tests for prostate cancer and were uncertain about the importance of associated risk factors. Some form of screening for prostate cancer is performed by 97.5% of GPs, and 50% of GPs support a national population-screening programme. 'Watchful waiting' is considered to be a reasonable treatment option for a man with localised prostate cancer and less than 10 years' life expectancy by 40% of GPs compared with 2% for a man with more than 10 years' life expectancy.
Most GPs undertake screening for prostate cancer, even though there is no evidence that screening improves life expectancy and quality of life.
确定全科医生（GPs）对前列腺癌筛查的看法。
向575名新西兰全科医生的全国随机样本发放问卷，样本按城乡全科医生数量相等进行分层。
问卷回复率为66.3%。对于前来进行年度体检或咨询前列腺癌筛查建议的55岁男性，74%的全科医生会为其进行前列腺特异性抗原（PSA）检测。如果该男性有前列腺癌或乳腺癌家族史，93%的全科医生会进行PSA检测。大多数全科医生高估了前列腺癌筛查检测的有效性，且对相关风险因素的重要性不确定。97.5%的全科医生会进行某种形式的前列腺癌筛查，50%的全科医生支持全国性人群筛查计划。40%的全科医生认为“密切观察等待”对于预期寿命不到10年的局限性前列腺癌男性是一种合理的治疗选择，而对于预期寿命超过10年的男性，这一比例为2%。
大多数全科医生进行前列腺癌筛查，尽管没有证据表明筛查能提高预期寿命和生活质量。
